Replies to post #4578 on Dendreon Corp fka DNDNQ

[rancherho]

1.The second Phase 2 trial apparently adds 22 patients who received high dose GVAX that is being used in Phase 3 and survived a median of 35 months. See: http://phx.corporate-ir.net/phoenix.zhtml?c=98399&p=irol-newsArticle&ID=981173&highlight...
While that only totals a group of 32 patients who survived a median 35 months, it may not prove a strong hypothetical treatment effect, but it certainly doesn't disprove it.
2. When you add developing strong MOA evidence that GVAX given in the high doses over 6 months used in the Ph3 trials precipitates a strong antibody response with consequent macrophage attack as well as a T cell response, it appears increasingly potent. IMO, it is foolish to discount the outcome of interim results. In addition, early Ph1 results of GVAX with ipilimumab, a CTLA4 blocker, also have shown bone met regression, an exceedingly difficult goal for any therapy to achieve. My point is that it is far too early to presume interim survival results of Provenge or GVAX especially when the unknown alpha spending for the interim look for each therapy is factored in. JMHO.